Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cocrystal Pharma, Inc.COCP · Entity 7621 | Director | January 09, 2026 | January 13, 2026 |
| OPKO HEALTH, INC.OPK · Entity 4891 | Director | March 12, 2020 | March 13, 2020 |
| Sanaby Health Acquisition Corp. ISANBU · Entity 134494 | Director | October 14, 2021 | October 15, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cocrystal Pharma, Inc.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2036-01-09 | Direct | 16,410 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 16,410 · Balance 16,410 F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.
OPKO HEALTH, INC.
Report date March 12, 2020 · Filed March 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,000 |
Reported balance
After 2020-03-12 transaction · row 1
1 source rowRow 1 · 2020-03-12 · Purchase · Acquired 500 · Balance 1,000 |
Sanaby Health Acquisition Corp. I
Report date October 14, 2021 · Filed October 15, 2021
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 13, 2026 21:10 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 16,410 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001493152-26-002034 · ownership.xml · derivative · entry 1 Japour Anthony J · CIK 0001773088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,410 Underlying: Common Stock · 16,410 shares Expires 2036-01-09 F1 · security: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date. F1 · derivative.exercise_date: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 20:05 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantCommon Stock | 14,924 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-040898 · ownership.xml · nonDerivative · entry 1 Japour Anthony J · CIK 0001773088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,924 F1 · security: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan. F1 · price: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:05 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 13,567 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001493152-23-025085 · ownership.xml · derivative · entry 1 Japour Anthony J · CIK 0001773088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,567 Underlying: Common Stock · 13,567 shares Expires 2033-07-18 F1 · derivative.exercise_date: The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 18, 2024 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date. Read SEC document |
| July 25, 2022 Filed Aug 3, 2022 20:51 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 148,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001493152-22-021187 · ownership.xml · derivative · entry 1 Japour Anthony J · CIK 0001773088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,000 Underlying: Common Stock · 148,000 shares Expires 2032-07-25 F1 · derivative.exercise_date: The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 25, 2023 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2023, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 20:05 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 74,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001493152-21-017324 · ownership.xml · derivative · entry 1 Japour Anthony J · CIK 0001773088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 74,000 shares Expires 2031-07-16 F1 · derivative.exercise_date: The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 16, 2022 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2022, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 22:50 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 56,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001493152-20-011751 · ownership.xml · derivative · entry 1 Japour Anthony J · CIK 0001773088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2030-06-22 F1 · derivative.exercise_date: The stock options vest as follows: 28,000 stock options will vest on the one year anniversary of the grant date and the remaining 28,000 stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on September 30, 2021. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 10:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 500 | $1.51 | $755.05 |
DisclosureSEC source: 0001209191-20-018669 · doc4.xml · nonDerivative · entry 1 Japour Anthony J · CIK 0001773088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 18:51 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 500 | $1.47 | $735.00 |
DisclosureSEC source: 0001209191-20-015941 · doc4.xml · nonDerivative · entry 1 Japour Anthony J · CIK 0001773088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:37 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001209191-20-002542 · doc4.xml · derivative · entry 1 Japour Anthony J · CIK 0001773088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-01-05 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.